Key result
Treatment for testicular cancer with chemotherapy (RR 2.59), radiotherapy (RR 2.40), or both (RR 2.78) was associated with a significantly increased risk of cardiovascular events versus surgery alone.
Why the study?
Does treatment with chemotherapy and/or radiotherapy increase the risk of cardiovascular events in long-term survivors of testicular cancer compared to orchidectomy alone?
Cohort (n=992)
Yes
Does treatment with chemotherapy and/or radiotherapy increase the risk of cardiovascular events in long-term survivors of testicular cancer compared to orchidectomy alone?
Effect estimate: RR 2.59 (chemotherapy), RR 2.40 (radiotherapy), RR 2.78 (both) (95% CI 1.15-5.84 (chemotherapy), 1.04-5.45 (radiotherapy), 1.09-7.07 (both))
p-value: p=0.022 (chemotherapy), 0.036 (radiotherapy), 0.032 (both)
Long-term survivors of testicular cancer treated with chemotherapy, radiotherapy, or both have a more than two-fold increased risk of cardiovascular events compared to those treated with orchidectomy alone, independent of traditional cardiac risk factors.
No takes yet. Share an insight, caveat, or question.
May support intensified CV monitoring in survivors; leaves open optimal risk mitigation strategies.
Huddart et al. (2003) conducted a cohort in Testicular cancer (n=992). Chemotherapy, radiotherapy, or both vs. Orchidectomy and follow-up only was evaluated on Cardiovascular events (RR 2.59 (chemotherapy), RR 2.40 (radiotherapy), RR 2.78 (both), 95% CI 1.15-5.84 (chemotherapy), 1.04-5.45 (radiotherapy), 1.09-7.07 (both), p=0.022 (chemotherapy), 0.036 (radiotherapy), 0.032 (both)). Treatment for testicular cancer with chemotherapy (RR 2.59), radiotherapy (RR 2.40), or both (RR 2.78) was associated with a significantly increased risk of cardiovascular events versus surgery alone.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: